SAN ANTONIO — More than half of patients with pretreated HER2-positive advanced or metastatic breast cancer who received the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) had ...
Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study. Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An ...
Prostate cancer begins as an androgen-dependent tumor that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results